PParis, France and Camberley, UK – 3 December 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by French law and is further summarised
Visit PageCategory: Board
NOVACYT SIGNS $3.0M DIAGNOSTICS SUPPLY AGREEMENT WITH GENESIS DIAGNOSTICS
PrimerDesign Genesis Diagnostics ENG Paris, France and Camberley, UK – 27th November 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign Ltd. (Primerdesign), has signed an exclusive supply agreement worth a minimum of $3 million with Genesis Diagnostics, a US-based full service diagnostic
Visit PageINFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers http://novacyt.com/wp-content/uploads/2018/11/NOVACYT_CP_Droits-de-vote_2018-Nov.pdf
Visit Page